The Future of Collaboration in the COVID-19 Pandemic

This week we welcome Dr. Alfred Kim to our show as we discuss B-Cell depleting therapies and how patients on these drugs may be more susceptible to COVID-19. During which, Dr. Kim takes us back to the beginning of the pandemic and how he and his patients initially managed the rituximab infusions, how and why people on this drug may be at increased risk of severe disease, the importance of vaccinations, and why they may not work for this patient population. Finally, we finish with Dr. Kim sharing with us important information on how to mitigate the risk of COVID-19 among people taking b-cell depleting therapies, now that there are new therapies for COVID-19 pre-exposure prophylaxis.